Caribou Biosciences (CRBU) Shares Outstanding (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Shares Outstanding (Entity) of $97.0 million for Q1 2026, up 4.24% year-over-year from $93.0 million in Q1 2025, and up 1.9% quarter-over-quarter from $95.1 million in Q4 2025.
Caribou Biosciences (CRBU) Shares Outstanding (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Shares Outstanding (Entity) for 7 consecutive years, with $97.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 4.24% year-over-year to $97.0 million; the TTM figure through Mar 2026 stood at $97.0 million (up 4.24% YoY), while the FY2025 annual figure was $95.1 million, up 2.99% from the prior year.
- Shares Outstanding (Entity) improved to $97.0 million in Q1 2026 per CRBU's latest filing, from $95.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $97.0 million in Q1 2026 and bottomed at $60.7 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $81.4 million across 5 years, with a median of $90.3 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 489.48% — and 2023, when it advanced 1.04%.
- Caribou Biosciences' Shares Outstanding (Entity) stood at $61.0 million in 2022, then surged by 44.93% to $88.4 million in 2023, then advanced by 4.44% to $92.4 million in 2024, then climbed by 2.99% to $95.1 million in 2025, then increased by 1.9% to $97.0 million in 2026.
- Business Quant data shows CRBU's Shares Outstanding (Entity) at $97.0 million in Q1 2026, $95.1 million in Q4 2025, and $93.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 100.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.99 Mn |
| Mar 31, 2026 | 95.86 Mn |
| Dec 31, 2025 | 93.39 Mn |
| Sep 30, 2025 | 93.29 Mn |
| Jun 30, 2025 | 93.03 Mn |
| Mar 31, 2025 | 92.68 Mn |
| Dec 31, 2024 | 90.32 Mn |
| Sep 30, 2024 | 90.46 Mn |
| Jun 30, 2024 | 90.34 Mn |
| Mar 31, 2024 | 89.30 Mn |
| Dec 31, 2023 | 73.81 Mn |
| Sep 30, 2023 | 83.78 Mn |
| Jun 30, 2023 | 61.42 Mn |
| Mar 31, 2023 | 61.19 Mn |
| Dec 31, 2022 | 60.80 Mn |
| Sep 30, 2022 | 60.89 Mn |
| Jun 30, 2022 | 60.76 Mn |
| Mar 31, 2022 | 60.55 Mn |
| Dec 31, 2021 | 31.66 Mn |
| Sep 30, 2021 | 45.89 Mn |